ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals

What ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals does

AMTAR (the ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals) is an Australian Government-funded research consortium established in September 2022 via a A$4.8 million grant from the Australian Research Council's Industrial Transformation Research Program and officially launched on 8 May 2024 at The University of Queensland's Centre for Advanced Imaging. Led by Hub Director Professor Kristofer Thurecht (UQ), with Deputy Directors Professor David Owen (UQ, Theme 2) and Professor Rachel Codd (University of Sydney, Theme 1), the hub convenes 63 listed researchers across radiochemistry, radiobiology, bioengineering, biotechnology, pharmaceutical evaluation, and health economics to develop new technologies and quality assurance frameworks for targeted radiopharmaceuticals used in cancer diagnosis and treatment. AMTAR operates as an ARC Industrial Transformation Research Hub rather than a commercial product company: it does not sell products or services, and instead distributes value through academic publications, collaborative research, talent development (postdoctoral and PhD programs), and technology transfer to industry partners.

The hub's research is structured around two complementary themes covering the full radiopharmaceutical supply chain. Theme 1 (Innovation in probes, radiochemistry and linker chemistry) covers chelator development for radionuclides including Ac-225, Ra-223, Pb-212, Bi-212, Zr-89, Ga-68, Cu-64, Lu-177, and Tb-161; novel linkers and bioconjugation chemistries; and enhanced radioisotope production methods. Theme 2 (Novel biologics and radiopharmaceutical manufacturing technologies) covers advanced biologics engineering (antibody fragments, nanobodies, peptides), microdosimetry and biological evaluation, and a quality assurance platform for manufactured radiopharmaceuticals. AMTAR partners with six core industry companies — AdvanCell Isotopes, Telix Pharmaceuticals, Clarity Pharmaceuticals, Starpharma, Cyclowest, and GlyTherix — and coordinates with national organizations (CSIRO, ANSTO, Royal Brisbane and Women's Hospital, National Biologics Facility, National Imaging Facility) and international institutions (Oak Ridge National Laboratory, Memorial Sloan Kettering Cancer Center, University of Nottingham, University of Tokyo).

The hub's go-to-market is community-led: it operates as a convening platform that addresses shared industry challenges in radiopharmaceutical manufacturing through seminars, annual symposiums, research retreats, conference participation (iSRS2025, Pacifichem 2025), and direct engagement via its website and social channels (LinkedIn, Twitter). Funding derives from the ARC grant envelope, ARC Linkage Project awards, industry partner co-funding and in-kind contributions, and the participating universities (UQ and Sydney). Outcomes are transferred to industry partners for commercialization rather than sold as discrete products, positioning AMTAR as a pre-competitive shared R&D platform rather than a commercial vendor.

Name

ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals

Legal name

ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals

Website

https://amtarhub.com.au

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

AMTAR is an Australian Research Council-funded research consortium developing technologies for the design, manufacture, and quality assurance of targeted radiopharmaceuticals for cancer diagnosis and treatment, convening academic researchers and industry partners across Australia and internationally.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industries

Small-Molecule API Process Development & Route Scouting (HLAGAHAA), Process Development & Tech Transfer (Upstream/Downstream/MSAT) (HLAGAGAE), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), Medical Oncology (HLAKAFAB)

Keywords

• Radiopharmaceutical research
• Targeted cancer therapy
• Radiochemistry research
• Medical imaging agents
• Biologics engineering research

Headquarters

HQ city

Brisbane

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Australian Research Council Funding: The hub is primarily funded by the Australian Government through the Australian Research Council Industrial Transformation Research Program. Initial funding was $4.8 million from the ARC to establish the hub.
2. Industry Partner Contributions: Industry partners provide co-funding and in-kind contributions to collaborative research projects. Partners include AdvanCell, Telix Pharmaceuticals, Clarity Pharmaceuticals, Starpharma, Cyclowest, and GlyTherix.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

AMTAR is a research consortium that develops new technologies for the smart-design, manufacture, and quality assurance of targeted radiopharmaceuticals used in cancer diagnosis and treatment. Its work spans chelator development, radioisotope production (Ac-225, Pb-212, Lu-177 and others), novel linkers and bioconjugation, advanced biologics engineering (antibody fragments, nanobodies, peptides), and microdosimetry/biological evaluation. The hub does not sell commercial products; research outcomes are transferred to industry partners for commercialisation.

Product overview

ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) is a research consortium, not a commercial product company. It does not offer products or services for sale. Rather, AMTAR is an Australian Government-funded research initiative established in 2023 to advance the science and manufacturing of targeted radiopharmaceuticals for cancer diagnosis and treatment. The hub conducts fundamental and applied research organized around two complementary themes: (1) Innovation in probes, radiochemistry and linker chemistry, encompassing chelator development, enhanced isotope production, and new linkers; and (2) Novel biologics and radiopharmaceutical manufacturing technologies, covering advanced biologics engineering, microdosimetry, and quality assurance. Research outcomes are transferred to industry partners for commercialization rather than sold as discrete products.

Differentiator

Problem solved

Functional benefit

Products and services

• Collaborative Radiopharmaceutical Research Multidisciplinary collaborative research and technology co-development covering chelator design, radioisotope production, linker chemistry, biologics engineering, microdosimetry and quality assurance, delivered to industry and academic partners via co-funded projects, postdoctoral programs, and joint publications.
• Industry Partnership Program Structured engagement program allowing industry partners (radiopharmaceutical companies) to access AMTAR's multidisciplinary expertise, facilities, and co-funded research projects via cash and in-kind contributions.
• Postdoctoral Researcher Opportunities Postdoctoral research positions embedded within AMTAR research projects, providing advanced training in radiopharmaceutical science to early-career researchers.
• PhD Opportunities PhD student research opportunities hosted within the AMTAR consortium across its two research themes, supporting development of the next generation of radiopharmaceutical researchers.

Quantifiable outcome

• Positioning Australia as a world-leader in radiopharmaceutical manufacture and innovation

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

21 partnerships are on record, tiered core, major and minor.

• AdvanCell IsotopescoreStrategic or Co-development Partner · 1 January 2023Industry partner specializing in radioisotope production. AMTAR Hub Director and CIs received ARC Linkage Project funding with AdvanCell exploring new materials for more efficient production of Pb-212. AdvanCell hosted AMTAR researchers for production facility site visit. CEO Dr Philina Lee gave seminar on career journey.
• Telix PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2023Radiopharmaceutical company developing imaging and therapeutic products. Collaborates with AMTAR on multiple projects including nanomedicine development, radiopharmaceutical research, and preclinical studies. Postdoctoral researchers work on projects with Telix.
• Clarity PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2023Radiopharmaceutical company developing targeted radiopharmaceuticals for cancer. Dr Ellen van Dam participated in expert panel at AMTAR Symposium 2026. Multiple researchers collaborate with Clarity on research projects.
• StarpharmacoreStrategic or Co-development Partner · 1 January 2023Company focused on dendrimer-based chemotherapeutics and radiopharmaceuticals. Dana Piovesan from Starpharma gave seminar on DEP-HER2 Radio program. Collaborates on targeted radiopharmaceutical development.
• CyclowestcoreStrategic or Co-development Partner · 1 January 2023Industry partner in radiopharmaceutical development. Representatives attended AMTAR Research Retreat 2025.
• GlyTherixcoreStrategic or Co-development Partner · 1 January 2023Immuno-oncology company developing targeted radiopharmaceuticals. Dr Yanling Lu and Dr Douglas Campbell gave seminar on career journeys and biologics development. Yanling leads CMC programs at GlyTherix.
• The University of QueenslandcoreStrategic or Co-development Partner · 1 January 2022Lead university partner hosting AMTAR headquarters at Centre for Advanced Imaging and Australian Institute for Bioengineering and Nanotechnology. Hub Director Prof Kris Thurecht is based at UQ.
• University of SydneycoreStrategic or Co-development Partner · 1 January 2022University partner with node led by Professor Rachel Codd. Provides expertise in coordination chemistry, organic synthetic chemistry, and radiometal ligand design. Professor Codd serves as Theme Leader for Theme 1.
• CSIROmajorStrategic or Co-development PartnerNational research organization collaborating on various projects. Jason Dowling from CSIRO is listed as team member. Provides expertise in computational and imaging research.
• ANSTO (Australian Nuclear Science and Technology Organisation)majorStrategic or Co-development PartnerNational nuclear research organization. Ivan Greguric from ANSTO is listed as team member. Provides expertise in radioisotope research and production.
• Royal Brisbane and Women's Hospital (RBWH)majorStrategic or Co-development PartnerNational partner providing clinical perspective. Professor Roslyn Francis is affiliated with RBWH and participates in AMTAR activities. Contributes to translational research and clinical trials.
• Oak Ridge National Laboratory (ORNL)majorStrategic or Co-development PartnerInternational partner from USA. Sandra Davern from ORNL leads Radioisotope R&D Section. ORNL showcased radioisotope production capabilities at Pacifichem conference. Contributed to symposium organization.
• Memorial Sloan Kettering Cancer Center (MSKCC)majorStrategic or Co-development PartnerInternational partner from USA. Professor Jason Lewis from MSKCC gave keynote at AMTAR Symposium 2026. Major cancer research center contributing expertise in radiopharmaceutical science.
• University of NottinghammajorStrategic or Co-development PartnerInternational partner from UK. Professor Cameron Alexander gave seminar on polymer therapeutics. Expert in polymer therapeutics and drug delivery.
• University of TokyomajorStrategic or Co-development PartnerInternational partner from Japan. Professor Tadayuki Takahashi is affiliate investigator. Contributes expertise in detector technologies relevant to nuclear medicine.
• FB RicemajorImplementation/ SI/ Consulting PartnerEducation partner providing IP workshop at AMTAR Research Retreat. Offers guidance on patenting and licensing in the radiopharmaceutical sector.
• National Imaging FacilitymajorStrategic or Co-development PartnerNational partner providing imaging infrastructure. Representatives attended AMTAR Research Retreat 2025.
• Q-TRaCEminorStrategic or Co-development PartnerPartner organization. Representative attended AMTAR Research Retreat 2025.
• National Biologics FacilityminorStrategic or Co-development PartnerAustralia's leading bio-manufacturing hub. A/Prof Seth Cheetham is Director of National Biologics Facility and team member.
• Centenary InstituteminorStrategic or Co-development PartnerResearch institute. Professor Philip Hogg is Deputy Director and team member, contributing cancer research expertise.
• Mater Research InstituteminorStrategic or Co-development PartnerResearch institute. Professor John Hooper leads Cancer Biology Research Group and is affiliate investigator. Conducting phase 1 clinical trials on theranostic agents.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Telix Pharmaceuticals: Commercial radiopharmaceutical company focused on targeted diagnostic and therapeutic radiopharmaceuticals, including urologic oncology and rare diseases. Core industry partner of AMTAR with active research collaboration and postdoctoral researcher placements.
• Starpharma: Australian biopharmaceutical company developing dendrimer-based drug delivery including DEP-HER2 radio program for targeted radiopharmaceuticals. AMTAR core industry partner with active seminar engagement.
• Clarity Pharmaceuticals: Clinical-stage radiopharmaceutical company developing targeted theranostic agents for cancer. AMTAR core industry partner collaborating on research projects with multiple AMTAR investigators.
• AdvanCell Isotopes: Australian radioisotope production company specializing in alpha-emitting isotopes including Pb-212 and Ac-225. Core AMTAR industry partner with joint ARC Linkage Project funding for Pb-212 production research.

Broad incumbents

• GE HealthCare (Radiopharma): Global medical imaging and radiopharmaceutical division of GE HealthCare. Operates in the same product category as AMTAR's research targets with broad portfolio of PET and SPECT imaging agents and theranostic products.
• Curium Pharma: Global nuclear medicine company with vertically integrated radiopharmaceutical manufacturing and distribution. Comparable in target market and isotope manufacturing focus to AMTAR's research themes.
• Lantheus Holdings: Global radiopharmaceutical company with established diagnostic and therapeutic radiopharmaceutical portfolio. Comparable in target market and product category to AMTAR's industry partners and represents the commercial-scale peer.
• Australian Nuclear Science and Technology Organisation (ANSTO): Australia's national nuclear research organization with isotope production capabilities. Major AMTAR partner providing radioisotope research and production expertise.

Emerging players

• Cyclowest: Australian radiopharmaceutical development company. AMTAR core industry partner participating in research retreats and collaborative projects.
• GlyTherix: Australian immuno-oncology company developing antibody-based targeted radiopharmaceuticals. AMTAR industry partner with researchers contributing biologics development expertise and CMC program leadership.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/arc-research-hub-for-advanced-manufacture-of-targeted-radiopharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals